Q4 2024 · 13F-HR
Boxer Capital Management, LLCholdings as filed
Filed 2025-02-14 · accession 0001213900-25-014345
$1.17B
Reported value
60
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | Revolution Medicines Inc | $187.2M | 15.9% | 4,279,464 | Common | SOLE |
| 85205L107 | SWTXUSD | Springworks Therapeutics Inc | $123.6M | 10.5% | 3,421,541 | Common | SOLE |
| 670703107 | NUVL | Nuvalent Inc | $87.7M | 7.47% | 1,120,192 | Common | SOLE |
| N5749R100 | 2GH | Merus N V | $79.9M | 6.80% | 1,900,000 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $50.2M | 4.28% | 1,727,388 | Common | SOLE |
| 03753U106 | APLSUSD | Apellis Pharmaceuticals Inc | $45.5M | 3.87% | 1,426,000 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $39.8M | 3.39% | 470,000 | Common | SOLE |
| 80706P103 | SRRK | Scholar Rock Hldg Corp | $32.4M | 2.76% | 750,000 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics Inc | $32.1M | 2.73% | 10,380,999 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $28.2M | 2.40% | 2,027,678 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences Inc | $23.9M | 2.03% | 1,602,200 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $23.5M | 2.00% | 600,000 | Common | SOLE |
| 52490G102 | LEGN | Legend Biotech Corp | $22.8M | 1.94% | 700,000 | Common | SOLE |
| 76029N106 | REPL | Replimune Group Inc | $21.8M | 1.85% | 1,796,341 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $21.2M | 1.81% | 6,000,000 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio Inc | $20.6M | 1.75% | 2,000,000 | Common | SOLE |
| 45258J102 | IMVT | Immunovant Inc | $20.4M | 1.74% | 825,000 | Common | SOLE |
| 04335A105 | ARVN | Arvinas Inc | $20.3M | 1.73% | 1,058,614 | Common | SOLE |
| 73730P108 | PSTXUSD | Poseida Therapeutics Inc | $19.2M | 1.63% | 2,000,000 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals Inc | $18.4M | 1.57% | 1,466,051 | Common | SOLE |
| 032724106 | ANAB | Anaptys Bio Inc | $17.2M | 1.47% | 1,300,000 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics Inc | $17.1M | 1.46% | 425,000 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics Inc | $15.1M | 1.29% | 671,358 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals I | $15.1M | 1.28% | 1,189,943 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $14.0M | 1.19% | 1,732,571 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $13.6M | 1.15% | 500,000 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $13.5M | 1.15% | 1,590,000 | Common | SOLE |
| N90064101 | QURE | Uniqure NV | $13.2M | 1.13% | 750,000 | Common | SOLE |
| 230031106 | CGEM | Cullinan Therapeutics Inc | $11.1M | 0.94% | 907,895 | Common | SOLE |
| 00773J202 | SYRE | Spyre Therapeutics Inc | $10.9M | 0.93% | 466,680 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics Inc | $10.6M | 0.90% | 563,067 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc | $9.9M | 0.85% | 1,000,000 | Common | SOLE |
| G72800108 | PRTA | Prothena Corp PLC | $9.6M | 0.81% | 690,000 | Common | SOLE |
| 471871202 | JSPR | Jasper Therapeutics Inc | $7.5M | 0.64% | 350,000 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics Inc | $7.3M | 0.62% | 946,915 | Common | SOLE |
| 16934W106 | CMRXEUR | Chimerix Inc | $7.2M | 0.61% | 2,060,000 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $6.8M | 0.58% | 355,500 | Common | SOLE |
| 03237H101 | AMLX | Amylyx Pharmaceuticals Inc | $6.6M | 0.56% | 1,750,000 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $5.5M | 0.47% | 750,000 | Common | SOLE |
| 28658R106 | CLYM | Climb Bio Inc | $4.7M | 0.40% | 2,603,190 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc | $4.5M | 0.38% | 250,000 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $4.2M | 0.35% | 752,000 | Common | SOLE |
| 492327101 | KROS | Keros Therapeutics Inc | $4.0M | 0.34% | 250,000 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $3.9M | 0.33% | 86,000 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $3.8M | 0.32% | 650,000 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics Inc | $3.8M | 0.32% | 2,635,000 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology Inc | $2.5M | 0.21% | 1,545,000 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc | $2.4M | 0.20% | 135,000 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc | $2.2M | 0.19% | 536,132 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc | $2.2M | 0.19% | 1,708,187 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals Inc | $1.4M | 0.12% | 450,000 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics I | $1.1M | 0.09% | 506,000 | Common | SOLE |
| 68572M106 | OBIO | Orchestra Biomed Hldgs Inc | $952,772 | 0.08% | 238,193 | Common | SOLE |
| G9TY5A101 | ZURA | Zura Bio Ltd | $750,000 | 0.06% | 300,000 | Common | SOLE |
| 59935V107 | MIST | Milestone Pharmaceuticals In | $729,257 | 0.06% | 309,007 | Common | SOLE |
| 10170A100 | BOLD | Boundless Bio Inc | $725,000 | 0.06% | 250,000 | Common | SOLE |
| 09077B104 | BCABGBP | BioAtla Inc | $405,768 | 0.03% | 686,347 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies S A | $154,500 | 0.01% | 50,000 | Common | SOLE |
| 67080N119 | NUVB/WS | Nuvation Bio Inc | $61,333 | 0.01% | 266,666 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen Inc | $1,660 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.